Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Cencora ( (COR) ) has issued an announcement.
Cencora, Inc. has successfully closed a $1.8 billion senior notes offering, comprised of $500 million in 2027 Notes, $600 million in 2029 Notes, and $700 million in 2035 Notes. The proceeds from this offering will be primarily used to finance the acquisition of Retina Consultants of America. This strategic move is intended to strengthen Cencora’s market position and support its ongoing operations. The offering marks a significant step in Cencora’s financial strategy as it terminated its $1.8 billion bridge financing commitments, reflecting the company’s adaptability in managing its financial obligations.
More about Cencora
Cencora is a leading global pharmaceutical solutions organization committed to enhancing health outcomes for people and animals worldwide. The company collaborates with pharmaceutical innovators to streamline market access to therapies, offering secure and reliable pharmaceutical delivery and healthcare solutions. With over 46,000 employees, Cencora is ranked #10 on the Fortune 500 and #24 on the Global Fortune 500, generating over $290 billion in annual revenue.
YTD Price Performance: 18.15%
Average Trading Volume: 1,441,135
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $46.49B
For detailed information about COR stock, go to TipRanks’ Stock Analysis page.
